{"id":105474,"date":"2026-04-19T13:08:11","date_gmt":"2026-04-19T11:08:11","guid":{"rendered":"https:\/\/cms.stage.munich-startup.gmbh\/startup\/modiblast-pharma\/"},"modified":"2026-04-19T13:08:11","modified_gmt":"2026-04-19T11:08:11","slug":"modiblast-pharma","status":"publish","type":"startup","link":"https:\/\/cms.stage.munich-startup.gmbh\/en\/startup\/modiblast-pharma\/","title":{"rendered":"Modiblast Pharma"},"content":{"rendered":"<div class=\"entry-content\"><p>Modiblast Pharma arbeitet daran, mit neuartigen dendritischen Zelltherapien f\u00fcr Blutkrebserkrankungen in die klinische Entwicklungsphase einzutreten. Der Schwerpunkt liegt auf dem Kernproblem akuter myeloischer Leuk\u00e4mien (AML) und myelodysplastischer Syndrome (MDS): der extrem hohen R\u00fcckfallquote nach erfolgreicher Ersttherapie.<\/p>\n<p>Der Modiblast-Ansatz (3 Patente erteilt) kombiniert Immunmodulatoren, um Blasten (Krebszellen) zu stimulieren, sich im Patienten (in vivo) in leuk\u00e4miespezifische dendritische Zellen (DCleu) zu differenzieren. Dadurch werden sowohl angeborene als auch adaptive Immunzellen im Blut und im Gewebe veranlasst, verbleibende oder wiederkehrende Blasten abzut\u00f6ten und Ged\u00e4chtniszellen zu erzeugen.<\/p>\n<p>Im Gegensatz zu z.B. CAR-T ist es nicht notwendig, spezifische Zielmolek\u00fcle zu identifizieren und auszuw\u00e4hlen. Au\u00dferdem sind keine komplizierten und teuren Ex-vivo-Zellextraktions- und -pr\u00e4parationsverfahren sowie GMP-Einrichtungen erforderlich.<\/p>\n<p>Unser langfristiges Ziel ist es, ein einfach anzuwendendes, selbst zu verabreichendes Medikament bereitzustellen, das die Remissionen stabilisieren oder das Fortschreiten der Krankheiten aufhalten kann. Diese Therapie kann auch die Thrombozyten-\/Neutrophilenzahl normalisieren.<\/p>\n<p>Der n\u00e4chste Schritt der klinischen Entwicklung ist eine Phase 1a\/2b-Studie, die vor kurzem die wissenschaftliche Beratung des BfArM bestanden hat.<\/p>\n<\/div>","protected":false},"featured_media":93829,"comment_status":"closed","ping_status":"closed","template":"","tags":[],"startup_industry":[5299,5325],"startup_businessmodel":[5265],"startup_stage":[5346],"class_list":["post-105474","startup","type-startup","status-publish","has-post-thumbnail","hentry","startup_industry-life-science","startup_industry-pharma","startup_businessmodel-b2b","startup_stage-seed-stage"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Modiblast Pharma - Munich Startup<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cms.stage.munich-startup.gmbh\/en\/startup\/modiblast-pharma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Modiblast Pharma - Munich Startup\" \/>\n<meta property=\"og:description\" content=\"Modiblast Pharma arbeitet daran, mit neuartigen dendritischen Zelltherapien f\u00fcr Blutkrebserkrankungen in die klinische Entwicklungsphase einzutreten. Der Schwerpunkt liegt auf dem Kernproblem akuter myeloischer Leuk\u00e4mien (AML) und myelodysplastischer Syndrome (MDS): der extrem hohen R\u00fcckfallquote nach erfolgreicher Ersttherapie. Der Modiblast-Ansatz (3 Patente erteilt) kombiniert Immunmodulatoren, um Blasten (Krebszellen) zu stimulieren, sich im &hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cms.stage.munich-startup.gmbh\/en\/startup\/modiblast-pharma\/\" \/>\n<meta property=\"og:site_name\" content=\"Munich Startup\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cms.stage.munich-startup.gmbh\/startup\/modiblast-pharma\/\",\"url\":\"https:\/\/cms.stage.munich-startup.gmbh\/startup\/modiblast-pharma\/\",\"name\":\"Modiblast Pharma - Munich Startup\",\"isPartOf\":{\"@id\":\"https:\/\/cms.stage.munich-startup.gmbh\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cms.stage.munich-startup.gmbh\/startup\/modiblast-pharma\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cms.stage.munich-startup.gmbh\/startup\/modiblast-pharma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cms.stage.munich-startup.gmbh\/wp-content\/uploads\/2023\/08\/Modiblast-Pharma.jpeg\",\"datePublished\":\"2026-04-19T11:08:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cms.stage.munich-startup.gmbh\/startup\/modiblast-pharma\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cms.stage.munich-startup.gmbh\/startup\/modiblast-pharma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.stage.munich-startup.gmbh\/startup\/modiblast-pharma\/#primaryimage\",\"url\":\"https:\/\/cms.stage.munich-startup.gmbh\/wp-content\/uploads\/2023\/08\/Modiblast-Pharma.jpeg\",\"contentUrl\":\"https:\/\/cms.stage.munich-startup.gmbh\/wp-content\/uploads\/2023\/08\/Modiblast-Pharma.jpeg\",\"width\":2400,\"height\":639,\"caption\":\"Modiblast Pharma GmbH\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cms.stage.munich-startup.gmbh\/startup\/modiblast-pharma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/cms.stage.munich-startup.gmbh\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Modiblast Pharma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cms.stage.munich-startup.gmbh\/#website\",\"url\":\"https:\/\/cms.stage.munich-startup.gmbh\/\",\"name\":\"Munich Startup\",\"description\":\"Das offizielle Startup-Portal f\u00fcr M\u00fcnchen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cms.stage.munich-startup.gmbh\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<meta property=\"og:image\" content=\"https:\/\/cms.stage.munich-startup.gmbh\/en\/wp-content\/uploads\/2023\/08\/Modiblast-Pharma.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2400\" \/>\n\t<meta property=\"og:image:height\" content=\"639\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Modiblast Pharma - Munich Startup","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cms.stage.munich-startup.gmbh\/en\/startup\/modiblast-pharma\/","og_locale":"en_US","og_type":"article","og_title":"Modiblast Pharma - Munich Startup","og_description":"Modiblast Pharma arbeitet daran, mit neuartigen dendritischen Zelltherapien f\u00fcr Blutkrebserkrankungen in die klinische Entwicklungsphase einzutreten. Der Schwerpunkt liegt auf dem Kernproblem akuter myeloischer Leuk\u00e4mien (AML) und myelodysplastischer Syndrome (MDS): der extrem hohen R\u00fcckfallquote nach erfolgreicher Ersttherapie. Der Modiblast-Ansatz (3 Patente erteilt) kombiniert Immunmodulatoren, um Blasten (Krebszellen) zu stimulieren, sich im &hellip;","og_url":"https:\/\/cms.stage.munich-startup.gmbh\/en\/startup\/modiblast-pharma\/","og_site_name":"Munich Startup","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cms.stage.munich-startup.gmbh\/startup\/modiblast-pharma\/","url":"https:\/\/cms.stage.munich-startup.gmbh\/startup\/modiblast-pharma\/","name":"Modiblast Pharma - Munich Startup","isPartOf":{"@id":"https:\/\/cms.stage.munich-startup.gmbh\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cms.stage.munich-startup.gmbh\/startup\/modiblast-pharma\/#primaryimage"},"image":{"@id":"https:\/\/cms.stage.munich-startup.gmbh\/startup\/modiblast-pharma\/#primaryimage"},"thumbnailUrl":"https:\/\/cms.stage.munich-startup.gmbh\/wp-content\/uploads\/2023\/08\/Modiblast-Pharma.jpeg","datePublished":"2026-04-19T11:08:11+00:00","breadcrumb":{"@id":"https:\/\/cms.stage.munich-startup.gmbh\/startup\/modiblast-pharma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cms.stage.munich-startup.gmbh\/startup\/modiblast-pharma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.stage.munich-startup.gmbh\/startup\/modiblast-pharma\/#primaryimage","url":"https:\/\/cms.stage.munich-startup.gmbh\/wp-content\/uploads\/2023\/08\/Modiblast-Pharma.jpeg","contentUrl":"https:\/\/cms.stage.munich-startup.gmbh\/wp-content\/uploads\/2023\/08\/Modiblast-Pharma.jpeg","width":2400,"height":639,"caption":"Modiblast Pharma GmbH"},{"@type":"BreadcrumbList","@id":"https:\/\/cms.stage.munich-startup.gmbh\/startup\/modiblast-pharma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/cms.stage.munich-startup.gmbh\/"},{"@type":"ListItem","position":2,"name":"Modiblast Pharma"}]},{"@type":"WebSite","@id":"https:\/\/cms.stage.munich-startup.gmbh\/#website","url":"https:\/\/cms.stage.munich-startup.gmbh\/","name":"Munich Startup","description":"The official startup portal for Munich","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cms.stage.munich-startup.gmbh\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]},"og_image":[{"width":2400,"height":639,"url":"https:\/\/cms.stage.munich-startup.gmbh\/wp-content\/uploads\/2023\/08\/Modiblast-Pharma.jpeg","type":"image\/jpeg"}]},"_links":{"self":[{"href":"https:\/\/cms.stage.munich-startup.gmbh\/en\/wp-json\/wp\/v2\/startup\/105474","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cms.stage.munich-startup.gmbh\/en\/wp-json\/wp\/v2\/startup"}],"about":[{"href":"https:\/\/cms.stage.munich-startup.gmbh\/en\/wp-json\/wp\/v2\/types\/startup"}],"replies":[{"embeddable":true,"href":"https:\/\/cms.stage.munich-startup.gmbh\/en\/wp-json\/wp\/v2\/comments?post=105474"}],"version-history":[{"count":0,"href":"https:\/\/cms.stage.munich-startup.gmbh\/en\/wp-json\/wp\/v2\/startup\/105474\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cms.stage.munich-startup.gmbh\/en\/wp-json\/wp\/v2\/media\/93829"}],"wp:attachment":[{"href":"https:\/\/cms.stage.munich-startup.gmbh\/en\/wp-json\/wp\/v2\/media?parent=105474"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cms.stage.munich-startup.gmbh\/en\/wp-json\/wp\/v2\/tags?post=105474"},{"taxonomy":"startup_industry","embeddable":true,"href":"https:\/\/cms.stage.munich-startup.gmbh\/en\/wp-json\/wp\/v2\/startup_industry?post=105474"},{"taxonomy":"startup_businessmodel","embeddable":true,"href":"https:\/\/cms.stage.munich-startup.gmbh\/en\/wp-json\/wp\/v2\/startup_businessmodel?post=105474"},{"taxonomy":"startup_stage","embeddable":true,"href":"https:\/\/cms.stage.munich-startup.gmbh\/en\/wp-json\/wp\/v2\/startup_stage?post=105474"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}